Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Abbisko Cayman Limited ( (HK:2256) ) is now available.
Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, has received Orphan Drug Designation from the U.S. Food and Drug Administration for its orally administered, highly selective FGFR2/3 inhibitor ABSK061 to treat achondroplasia. The candidate, designed to address aberrant FGFR3 activation underlying the rare genetic growth disorder, is in a Phase II trial in children aged three to twelve, with initial data expected in the second half of 2026.
The new status, coming on top of an existing Rare Pediatric Disease designation, brings potential benefits including tax credits, user-fee waivers and post-approval market exclusivity that could strengthen ABSK061’s U.S. development and commercialization prospects. These regulatory incentives are set to support Abbisko’s push to accelerate global clinical progress and may enhance its strategic position in the emerging market for targeted therapies for pediatric achondroplasia.
The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biopharmaceutical industry with a focus on developing innovative small-molecule therapies. The group is advancing targeted inhibitors such as ABSK061 for rare genetic diseases, with a particular emphasis on conditions driven by fibroblast growth factor receptor (FGFR) pathway abnormalities.
Average Trading Volume: 1,704,958
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.39B
Learn more about 2256 stock on TipRanks’ Stock Analysis page.